

15 December 2020

SourceBio International plc  
("SourceBio", the "Company" or the "Group")

### Commercial agreement for COVID-19 testing service

*Oxford Nanopore's rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities*

SourceBio International plc (AIM:SBI), an international provider of integrated state of the art laboratory services and products, announces that it has entered into a strategic commercial partnership with Oxford Nanopore Technologies Limited ("Oxford Nanopore"), a leading next generation DNA/RNA sequencing technology company, to offer a commercially available COVID-19 testing solution to corporate customers at scale. The test will also be offered to consumers.

Oxford Nanopore's, CE-marked LamPORE COVID-19 assay, for the detection of SARS-CoV-2, will be used at SourceBio's state-of-the-art ISO15189 accredited laboratory facility in Nottingham to offer a large-scale COVID-19 diagnostic testing service.

LamPORE COVID-19, a new generation of test, is specifically designed to detect SARS-CoV-2, the virus that causes COVID-19. LamPORE is rapid and highly scalable, allowing for high performance test deployment in both high-throughput, traditional laboratory settings as well as smaller, more local lab environments – addressing the need for rapid, routine testing of large numbers of people. LamPORE has been shown to have sensitivity of 99.1% and specificity of 99.6%.

In this instance, the LamPORE COVID-19 test is performed from oropharyngeal and nasopharyngeal swabs which are sent to SourceBio for assessment and can return a positive or negative result within 24 hours of the laboratory receiving the sample. LamPORE also includes a built-in human actin control, which enables operators to discriminate between negative results due to sample collection errors and negative results due to the absence of SARS-CoV-2 infection.

With options for using LamPORE in a fixed laboratory, or even in mobile community testing, the service is expected to broaden access to rapid, high quality testing to support people to return to work, to visit friends and relatives safely, and potentially assist with international travel where testing is accepted or required, given that LamPORE is a high-accuracy molecular test.

The COVID-19 testing service using LamPORE will be offered as an additional service by SourceBio to complement its existing COVID-19 PCR Testing services which are currently used by a range of customers.

SourceBio and Oxford Nanopore are already jointly marketing this service to potential corporate customers. Potential corporate customers can register their interest here <https://register.nanoporetech.com/lampore-source-bioscience>. Private individuals can access the service here: <https://coviduk.sourcebioscience.com>

**Jay LeCoque, Executive Chairman of SourceBio International plc, said:** *"The commercial relationship that we have developed with Oxford Nanopore is a valuable partnership that delivers essential testing technology and a high-quality service offering at a crucial time in the worldwide effort to combat and manage the further spread of Coronavirus. This alliance effectively creates a 'total solutions approach' for both companies' offerings by combining Oxford Nanopore's leading LamPORE COVID-19 test with our UKAS accredited laboratory services. This combination allows both companies to provide clients with a high quality, highly scalable and highly professional product and a fully accredited laboratory services capability."*

*“The UK Government has minimum standards for private sector providers of COVID-19 testing and we are delighted to have been awarded full UKAS ISO15189 status for our COVID testing. Very few commercial institutions have received this standard and it is a mandatory requirement from next summer 2021. This underscores the high standard of our accredited testing services and provides us with a significant advantage in the market.”*

**Gordon Sanghera, Co-founder and Chief Executive Officer at Oxford Nanopore Technologies Limited, said:** *“We are delighted that high quality COVID-19 testing with LamPORE will now be available privately in the UK through the high-quality labs of Source Bioscience. As the UK rolls out a vaccine programme, the importance of safeguarding workforces and customers, as well as friends and family, remains a priority for many businesses and individuals. We are committed to being part of the solution in the UK public and private sectors, and pleased that our technology can support a transition back to work, leisure and family life.”*

#### **Contacts:**

##### **SourceBio International plc**

Jay LeCoque, Executive Chairman  
Tony Ratcliffe, Chief Financial Officer

[www.sourcebiointernational.com](http://www.sourcebiointernational.com)

Via Walbrook PR

##### **Liberum (Nominated Adviser and Broker)**

Bidhi Bhoma  
Joshua Hughes  
Euan Brown

Tel: 020 3100 2000

##### **Walbrook PR Limited**

Paul McManus / Sam Allen

Tel: 020 7933 8780 or [sourcebio@walbrookpr.com](mailto:sourcebio@walbrookpr.com)

Mob: 07980 541 893 / 07748 651 727

#### **About Oxford Nanopore Technologies Limited [www.nanoporetech.com/about-us](http://www.nanoporetech.com/about-us)**

Oxford Nanopore has developed and commercialises a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible and easy to use in any location. The Company’s goal is to disrupt the way that biological analyses are currently performed; to enable the analysis of anything, by anyone, anywhere.

The palm-sized portable MinION device, and desktop GridION and PromethION devices, are used in a broad range of scientific analyses, across human genetics, cancer research, agriculture, food safety, healthcare and environmental insights. Most recently, Oxford Nanopore has launched the MinION Mk1C, a fully connected sequencer with screen and compute, and has also developed the LamPORE COVID-19 test. [www.nanoporetech.com](http://www.nanoporetech.com)

#### **About SourceBio International plc [www.sourcebiointernational.com](http://www.sourcebiointernational.com)**

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:

- **Healthcare Diagnostics** - histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
- **Genomics** - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.

- **Stability Storage** - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA; and
- **Infectious Disease Testing** - since May 2020, the Group has provided COVID-19 Antigen RT-PCR testing services. These services passed all of the auditing requirements of the NHS and the Department of Health and Social Care (DHSC) in April 2020. It is intended that this offering will potentially provide a broad range of infectious disease testing across the NHS, private healthcare and commercial sectors in the future.

More details on Group operations can be found here: [www.sourcebioscience.com](http://www.sourcebioscience.com)

SourceBio International plc (SBI.L) is listed on the AIM market of the London Stock Exchange.